Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTXNASDAQ:CMPSNASDAQ:IMMPNASDAQ:ORKA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.69+9.0%$1.60$1.20▼$7.38$95.78M2.631.48 million shs1.13 million shsCMPSCOMPASS Pathways$3.76+0.6%$3.34$2.49▼$8.87$348.54M2.27800,410 shs584,993 shsIMMPImmutep$1.87-3.4%$1.70$1.32▼$3.34$272.36M1.8220,717 shs329,656 shsORKAOruka Therapeutics$9.75+2.2%$9.96$5.49▼$31.13$365.05M0.25232,339 shs120,688 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics+5.80%-8.82%+13.97%-38.49%-78.47%CMPSCOMPASS Pathways+2.12%-6.61%+37.67%-19.72%-56.48%IMMPImmutep-4.93%+12.87%+35.92%-4.93%-33.90%ORKAOruka Therapeutics+2.37%-8.91%+24.80%-27.29%+950,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDTXBlack Diamond Therapeutics3.3887 of 5 stars3.54.00.00.02.72.51.3CMPSCOMPASS Pathways2.4101 of 5 stars3.53.00.00.03.00.80.6IMMPImmutep1.6118 of 5 stars3.53.00.00.02.20.00.0ORKAOruka Therapeutics3.0861 of 5 stars3.60.00.00.02.74.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 3.00Buy$14.60763.91% UpsideCMPSCOMPASS Pathways 3.00Buy$20.20437.09% UpsideIMMPImmutep 3.00Buy$8.50355.76% UpsideORKAOruka Therapeutics 3.22Buy$39.86308.79% UpsideCurrent Analyst Ratings BreakdownLatest BDTX, CMPS, ORKA, and IMMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/19/2025BDTXBlack Diamond TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.003/18/2025BDTXBlack Diamond TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $12.003/7/2025BDTXBlack Diamond TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.003/7/2025BDTXBlack Diamond TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00 ➝ $11.003/7/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.003/4/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $45.002/28/2025CMPSCOMPASS PathwaysCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $15.002/27/2025CMPSCOMPASS PathwaysStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$11.002/13/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $45.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond TherapeuticsN/AN/AN/AN/A$2.26 per shareN/ACMPSCOMPASS PathwaysN/AN/AN/AN/A$3.65 per shareN/AIMMPImmutep$5.14M52.99N/AN/A$1.05 per share1.78ORKAOruka TherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$82.44M-$1.27N/AN/AN/AN/A-68.08%-49.65%5/8/2025 (Estimated)CMPSCOMPASS Pathways-$118.46M-$2.30N/AN/AN/AN/A-63.85%-51.97%5/8/2025 (Estimated)IMMPImmutep-$28.01MN/A0.00N/AN/AN/AN/AN/AN/AORKAOruka Therapeutics-$5.34M-$5.79N/AN/AN/AN/A-24.96%-21.22%5/8/2025 (Estimated)Latest BDTX, CMPS, ORKA, and IMMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025BDTXBlack Diamond Therapeutics$0.10N/AN/AN/A$23.33 millionN/A5/8/2025Q1 2025CMPSCOMPASS Pathways-$0.47-$0.44+$0.03-$0.24N/AN/A5/8/2025Q1 2025ORKAOruka Therapeutics-$0.57N/AN/AN/AN/AN/A3/6/2025Q4 2024BDTXBlack Diamond Therapeutics-$0.31-$0.28+$0.03-$0.28N/AN/A3/6/2025Q4 2024ORKAOruka Therapeutics-$0.68-$0.49+$0.19-$0.49N/AN/A2/27/2025Q4 2024CMPSCOMPASS Pathways-$0.62-$0.63-$0.01-$0.63N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/AIMMPImmutepN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A5.555.55CMPSCOMPASS Pathways0.158.918.91IMMPImmutep0.0118.2518.25ORKAOruka TherapeuticsN/A22.8922.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%CMPSCOMPASS Pathways46.19%IMMPImmutep2.32%ORKAOruka Therapeutics56.44%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics8.87%CMPSCOMPASS Pathways4.25%IMMPImmutep3.07%ORKAOruka Therapeutics22.67%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.68 million51.57 millionOptionableCMPSCOMPASS Pathways12092.67 million65.51 millionOptionableIMMPImmutep2,021146.04 million141.09 millionOptionableORKAOruka TherapeuticsN/A37.44 million27.07 millionN/ABDTX, CMPS, ORKA, and IMMP HeadlinesRecent News About These CompaniesBraidwell LP Acquires 631,950 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)May 8 at 6:30 AM | marketbeat.comBlackstone Inc. Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)May 8 at 6:21 AM | marketbeat.comBarclays PLC Purchases Shares of 74,583 Oruka Therapeutics, Inc. (NASDAQ:ORKA)May 6 at 3:26 AM | marketbeat.comTrinity Biotech (NASDAQ:TRIB) vs. Oruka Therapeutics (NASDAQ:ORKA) Critical ContrastMay 5 at 1:49 AM | americanbankingnews.com683 Capital Management LLC Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)May 4, 2025 | marketbeat.comQ1 EPS Forecast for Oruka Therapeutics Reduced by AnalystMay 3, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Grows Stock Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)May 3, 2025 | marketbeat.comQ1 EPS Estimates for Oruka Therapeutics Cut by HC WainwrightMay 3, 2025 | americanbankingnews.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Buy" by BrokeragesMay 3, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for ORKA Q1 Earnings?May 2, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Sold by Adage Capital Partners GP L.L.C.May 2, 2025 | marketbeat.comQ1 Earnings Estimate for ORKA Issued By HC WainwrightMay 2, 2025 | americanbankingnews.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of "Buy" from BrokeragesMay 1, 2025 | americanbankingnews.comOruka Therapeutics to Present at Bank of America Securities 2025 Health Care ConferenceApril 29, 2025 | globenewswire.comGeode Capital Management LLC Boosts Stock Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)April 28, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Bought by SR One Capital Management LPApril 19, 2025 | marketbeat.comOruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on ThursdayApril 18, 2025 | marketbeat.comKennedy Capital Management LLC Buys Shares of 60,494 Oruka Therapeutics, Inc. (NASDAQ:ORKA)April 17, 2025 | marketbeat.comFmr LLC Increases Stock Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)April 16, 2025 | marketbeat.comVanguard Group Inc. Acquires 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)April 16, 2025 | marketbeat.comWhy Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 6.65%April 16, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDTX, CMPS, ORKA, and IMMP Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$1.69 +0.14 (+9.03%) Closing price 04:00 PM EasternExtended Trading$1.71 +0.02 (+1.12%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.COMPASS Pathways NASDAQ:CMPS$3.76 +0.02 (+0.56%) Closing price 03:59 PM EasternExtended Trading$3.77 +0.01 (+0.24%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Immutep NASDAQ:IMMP$1.86 -0.07 (-3.37%) Closing price 03:59 PM EasternExtended Trading$1.83 -0.03 (-1.82%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Oruka Therapeutics NASDAQ:ORKA$9.75 +0.21 (+2.20%) Closing price 03:59 PM EasternExtended Trading$9.75 0.00 (0.00%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
